|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03113604 |
|
Date of registration:
|
10/04/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
SLAMF3 |
|
Scientific title:
|
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients |
|
Date of first enrolment:
|
November 20, 2015 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
https://clinicaltrials.gov/show/NCT03113604 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients over 18 years of age,
- Diagnosis of hepatocellular carcinoma (histological or non-invasive criteria of
Barcelona),
Group 1: Tumor and peri-tumor tissue samples from patients with untreated CHCs sorafenib
- Patients who received treatment other than sorafenib (chemo-embolization, radiofrequency,
resection, ...),
Group 2: Tumor and peri-tumor tissue samples from patients with non-sorafenib CHC
- Patients treated with sorafenib,
- Patients not responding to treatment with sorafenib
Group 3: Tumor and peri-tumor tissue samples from patients with CHCs responding to
sorafenib
- Patients treated with sorafenib,
- Patients responding to treatment with sorafenib
Exclusion Criteria:
- Age <18 years,
- Patients who do not have liver biopsy specimens (PBH) available at the tumor bank,
- Patients who have refused to use their samples for biomedical research,
- Pregnancy and breast feeding
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Hepatocellular Carcinoma
|
|
Hepatocyte Receptor
|
|
Intervention(s)
|
|
Other: Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
|
|
Primary Outcome(s)
|
|
Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib
[Time Frame: 1 day]
|
|
Secondary ID(s)
|
|
PI2015_843_0021
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|